Alpha 2.0
Login Register
» Authors » Wouter W van Solinge

Wouter W van Solinge

Explore the profile of Wouter W van Solinge including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 152
Citations 2656
Followers 0
Related Specialties
Hematology
Biochemistry
Pharmacology
Top 10 Co-Authors
Richard van Wijk
Saskia Haitjema
Imo E Hoefer
Maarten J Ten Berg
Albert Huisman
Karen M K de Vooght
Toine C G Egberts
Raymond M Schiffelers
Brigitte A van Oirschot
Gerard Pasterkamp
Published In
Clin Chem Lab Med
Am J Hematol
Haematologica
J Med Internet Res
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Comparison of estimated glomerular filtration rate equations on prediction of mortality, kidney failure, and acute kidney injury
Veltkamp D, Rookmaaker M, de Groot M, Verhaar M, van Solinge W, Haitjema S, et al.
Nephrol Dial Transplant . 2025 Mar; PMID: 40068936
Background: The CKD-EPIASR-NB2009 estimated glomerular filtration rate (eGFR) equation has shown substantial overestimation of GFR in Europeans, hence new equations have been developed. We examined the effect of introducing the...
2.
Haematology dimension reduction, a large scale application to regular care haematology data
Joosse H, Chumsaeng-Reijers C, Huisman A, Hoefer I, van Solinge W, Haitjema S, et al.
BMC Med Inform Decis Mak . 2025 Feb; 25(1):75. PMID: 39939843
Background: The routine diagnostic process increasingly entails the processing of high-volume and high-dimensional data that cannot be directly visualised. This processing may provide scaling issues that limit the implementation of...
3.
Improving acute kidney injury alerts in tertiary care by linking primary care data: An observational cohort using routine care data
Joosse H, Groenestege W, Vernooij R, De Groot M, Hoefer I, van Solinge W, et al.
Digit Health . 2024 Aug; 10:20552076241271767. PMID: 39161342
Objective: Acute kidney injury (AKI) is easily missed and underdiagnosed in routine clinical care. Timely AKI management is important to decrease morbidity and mortality risks. We recently implemented an AKI...
4.
Comparison of the Response to an Electronic Versus a Traditional Informed Consent Procedure in Terms of Clinical Patient Characteristics: Observational Study
Zondag A, Hollestelle M, van der Graaf R, Nathoe H, van Solinge W, Bots M, et al.
J Med Internet Res . 2024 Jul; 26:e54867. PMID: 38990640
Background: Electronic informed consent (eIC) is increasingly used in clinical research due to several benefits including increased enrollment and improved efficiency. Within a learning health care system, a pilot was...
5.
Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease
van Dijk M, Ruiter T, van der Veen S, Rab M, van Oirschot B, Bos J, et al.
Hemasphere . 2024 Jun; 8(6):e109. PMID: 38919958
Mitapivat is an investigational, oral, small-molecule allosteric activator of pyruvate kinase (PK). PK is a regulatory glycolytic enzyme that is key in providing the red blood cell (RBC) with sufficient...
6.
The Effect of Artificial Intelligence on Patient-Physician Trust: Cross-Sectional Vignette Study
Zondag A, Rozestraten R, Grimmelikhuijsen S, Jongsma K, van Solinge W, Bots M, et al.
J Med Internet Res . 2024 May; 26:e50853. PMID: 38805702
Background: Clinical decision support systems (CDSSs) based on routine care data, using artificial intelligence (AI), are increasingly being developed. Previous studies focused largely on the technical aspects of using AI,...
7.
A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease
van Dijk M, Traets M, van Oirschot B, Ruiter T, de Wilde J, Bos J, et al.
EJHaem . 2024 Feb; 5(1):21-32. PMID: 38406513
The most common forms of sickle cell disease (SCD) are sickle cell anemia (SCA; HbSS) and HbSC disease. In both, especially the more dense, dehydrated and adherent red blood cells...
8.
One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study
van Dijk M, Rab M, van Oirschot B, Bos J, Derichs C, Rijneveld A, et al.
Blood Adv . 2023 Nov; 7(24):7539-7550. PMID: 37934880
Targeting the primary pathogenic event of sickle cell disease (SCD), the polymerization of sickle hemoglobin (HbS), may prevent downstream clinical events. Mitapivat, an oral pyruvate kinase (PK) activator, has therapeutic...
9.
Sexual dimorphism in peripheral blood cell characteristics linked to recanalization success of endovascular thrombectomy in acute ischemic stroke
Overmars L, van Solinge W, den Ruijter H, van der Worp H, van Es B, Hulsbergen-Veelken C, et al.
J Thromb Thrombolysis . 2023 Aug; 56(4):614-625. PMID: 37596427
Endovascular thrombectomy (EVT) success to treat acute ischemic stroke varies with factors like stroke etiology and clot composition, which can differ between sexes. We studied if sex-specific blood cell characteristics...
10.
A cluster of blood-based protein biomarkers associated with decreased cerebral blood flow relates to future cardiovascular events in patients with cardiovascular disease
Overmars L, Kuipers S, van Es B, de Bresser J, Bron E, Hoefer I, et al.
J Cereb Blood Flow Metab . 2023 Aug; 43(12):2060-2071. PMID: 37572101
Biological processes underlying decreased cerebral blood flow (CBF) in patients with cardiovascular disease (CVD) are largely unknown. We hypothesized that identification of protein clusters associated with lower CBF in patients...